证券日报网讯1月9日，济民健康（603222）在互动平台回答投资者提问时表示，公司控股子公司博鳌国 际医院的DB006溶瘤腺病毒注射液项目当前处于CDE补充材料审评阶段，状态显示"暂停"属正常流程， 待10-25个工作日补充材料审评完成后将恢复计时推进。 ...

此外，据田云飞介绍，公司此前引发投资者关注的"何清红等人伪造公司印章"案，截至目前，公安机关 已初步查明"何清红等人伪造公司印章"案的基本事实，何清红已由黄岩区检察院批准逮捕，相关案件仍 在进一步侦查中。 （上证路演） (编辑：杨燕 林辰)关键字： 医疗 近日，济民健康举办第三季度业绩说明会，在回答投资者普遍关注的创新药DB006溶瘤腺病毒注射液相 关进展时，济民健康董事兼总裁田云飞表示，DB006溶瘤腺病毒注射液临床试验受理已满60日，博鳌国 际医院未收到国家药监局药品审评中心对DB006临床试验的否定和质疑意见，博鳌国际医院将按计划推 进相关工作。博鳌国际医院DB006项目目前正稳步推进中，尚未正式启动临床试验工作。 博鳌国际医院DB006溶瘤腺病毒注射液是一款用于治疗晚期恶性实体肿瘤的基因治疗药物，该产品利用 基因工程的方法，对溶瘤病毒进行了多个方面的改造，以实现选择性感染肿瘤细胞、增强病毒的肿瘤特 异性复制能力；同时，该产品通过多个抗肿瘤及免疫调节基因的导入，利用多个靶点杀伤肿瘤。截至目 前，全球市场共有5个溶瘤病毒药物获得审批上市，国内市场进入临床试验阶段的溶瘤病毒药物约7个， 多数处于I/II期。 ...

Core Viewpoint - Jimin Health (603222.SH) is transitioning from a focus on large-volume infusion, medical devices, and healthcare services to becoming an innovative pharmaceutical company, marked by the acceptance of a clinical trial application for DB006 on September 26, 2025 [1]. Group 1: Company Transition - Jimin Health's subsidiary, Boao International Hospital, received a clinical trial acceptance notice for DB006, a oncolytic adenovirus injection, indicating the company's first step towards becoming an innovative drug enterprise [1]. - The registration classification of DB006 is as a Class 1 therapeutic biological product, signifying a significant shift in Jimin Health's business model since its establishment in 1996 [1]. Group 2: Market Context - In 2020, China reported 4.57 million new cancer cases and 3 million cancer deaths, with high incidence and mortality rates for liver, stomach, esophageal, and cervical cancers [1]. - Breast cancer has the highest incidence rate, followed by lung and colorectal cancers, with lung cancer remaining the leading cause of cancer-related deaths [1]. Group 3: Oncolytic Virus Therapy - Oncolytic virus therapy is recognized as a promising new type of cancer treatment, characterized by high efficiency in killing tumor cells, specificity, safety, low side effects, and cost-effectiveness [2]. - Currently, five oncolytic virus drugs have been approved globally, with approximately seven oncolytic virus drugs in clinical trials in China, most in Phase I/II [2]. Group 4: Product Details - DB006 is designed for the treatment of advanced malignant solid tumors, utilizing genetic engineering to enhance tumor-specific replication and selectively infect tumor cells [2]. - In preclinical models, DB006 demonstrated over 70% tumor suppression in colon cancer models and complete tumor remission in non-small cell lung cancer models [2]. Group 5: Financial Performance - In the first half of 2025, Jimin Health reported total revenue of 366 million yuan, a decrease of 21.3% year-on-year, with a net loss attributable to shareholders of 52.7 million yuan [3]. - The company attributed its losses to reduced revenue and profit from medical devices due to U.S. tariff policies and inventory write-downs related to specific products [3].

Core Viewpoint - Jimin Health (603222) announced that its subsidiary, Hainan Jimin Boao International Hospital Co., Ltd., received the acceptance notice for the clinical trial application of DB006 on September 26, 2025, from the National Medical Products Administration's Center for Drug Evaluation (CDE) [1] Company Summary - The DB006 oncolytic adenovirus injection is a gene therapy drug aimed at treating advanced malignant solid tumors [1]

Core Viewpoint - Jimin Health (603222.SH) announced that its subsidiary, Hainan Jimin Boao International Hospital, received a clinical trial acceptance notice from the National Medical Products Administration for the DB006 oncolytic adenovirus injection, indicating progress in its gene therapy development for advanced malignant solid tumors [1] Group 1 - The Boao International Hospital's DB006 oncolytic adenovirus injection is designed for the treatment of advanced malignant solid tumors [1] - The product utilizes genetic engineering to modify oncolytic viruses for selective infection of tumor cells and enhanced tumor-specific replication capabilities [1] - The therapy incorporates multiple anti-tumor and immune-regulating genes to target and kill tumors through various pathways [1]

Core Viewpoint - Jimin Health (603222.SH) announced that its subsidiary, Hainan Jimin Boao International Hospital, received a clinical trial acceptance notice from the National Medical Products Administration (NMPA) for the DB006 oncolytic adenovirus injection, aimed at treating advanced malignant solid tumors [1] Group 1: Company Developments - The Boao International Hospital's DB006 oncolytic adenovirus injection is a gene therapy drug designed for advanced malignant solid tumors [1] - The product utilizes genetic engineering to modify oncolytic viruses for selective infection of tumor cells and enhanced tumor-specific replication capabilities [1] - The drug incorporates multiple anti-tumor and immune-regulating genes to target and kill tumors through various mechanisms [1]